US2004219153A1PendingUtilityA1

Synergistic tumorcidal response induced by histamine

55
Priority: Jan 6, 1999Filed: Jun 2, 2004Published: Nov 4, 2004
Est. expiryJan 6, 2019(expired)· nominal 20-yr term from priority
Inventors:Kurt R. GehlsenKristoffer HellstrandSvante Hermodsson
A61P 35/02A61P 35/00A61K 39/395A61K 31/417A61K 41/0038
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.

Claims

exact text as granted — not AI-modified
1 . An improved cancer therapy, wherein the cancer therapy is selected from the group consisting of surgery, radiation, immunotherapy, and administration of an agent that enhances the humoral response of a subject, the improvement comprising administering to a subject an amount of a pharmaceutically acceptable form of histamine sufficient to synergistically inhibit a cancer, wherein said cancer is sensitive to the combination of said at least one cancer therapy and histamine synergistically.  
     
     
         2 . The improved cancer therapy of  claim 1 , wherein the cancer therapy is a radiation therapy selected from the group consisting of external beam radiation, radionucleotides, radioactive implants, radioactive antibodies, radioactive lipids, radioactive proteins, radioactive glycolipids, and radioactive glycoproteins.  
     
     
         3 . The improved cancer therapy of  claim 1 , wherein the cancer therapy is an agent selected from the group consisting of a viral antigen, a cancer cell antigen, and an inactivated cancer cell.  
     
     
         4 . The improved cancer therapy of  claim 1 , wherein the cancer therapy is a surgery.  
     
     
         5 . The improved cancer therapy of  claim 1 , wherein the cancer therapy is an immunotherapy.  
     
     
         6 . The improved cancer therapy of  claim 5 , wherein the immunotherapy is an antibody.  
     
     
         7 . The improved cancer therapy of  claim 6 , wherein the antibody is a monoclonal antibody.  
     
     
         8 . The improved cancer therapy of  claim 1 , wherein the cancer is a stomach cancer.  
     
     
         9 . The improved cancer therapy of  claim 1 , wherein the cancer is a pancreatic cancer.  
     
     
         10 . The improved cancer therapy of  claim 1 , wherein the cancer is an ovarian cancer.  
     
     
         11 . The improved cancer therapy of  claim 1 , wherein the cancer is a prostate cancer.  
     
     
         12 . The improved cancer therapy of  claim 1 , wherein the cancer is a neuroblastoma.  
     
     
         13 . The improved cancer therapy of  claim 1 , wherein the cancer is a melanoma.  
     
     
         14 . The improved cancer therapy of  claim 1 , wherein the cancer is a breast cancer.  
     
     
         15 . The improved cancer therapy of  claim 1 , wherein the cancer is an acute myleogenous leukemia.  
     
     
         16 . The improved cancer therapy of  claim 1 , wherein the cancer is a chronic lymphatic leukemia.  
     
     
         17 . The improved cancer therapy of  claim 1 , wherein the cancer is a multiple myeloma.  
     
     
         18 . The improved cancer therapy of  claim 1 , wherein the cancer is a Waldenstrom's macroglobinemia.  
     
     
         19 . The improved cancer therapy of  claim 1 , wherein the cancer is a hairy cell leukemia.  
     
     
         20 . The improved cancer therapy of  claim 1 , wherein the cancer therapy is a radiation therapy.  
     
     
         21 . The improved cancer therapy of  claim 1 , wherein said cancer is a solid tumor disease.

Join the waitlist — get patent alerts

Track US2004219153A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.